STOCK TITAN

Protalix Biother - PLX STOCK NEWS

Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.

Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical innovator leveraging its proprietary ProCellEx® plant cell-based technology to develop enzyme replacement therapies for rare diseases. This page provides investors and industry stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.

Access comprehensive coverage of PLX's advancements in treating Gaucher disease, Fabry disease, and other rare conditions. Track updates across three key areas: clinical trial progress for pipeline candidates, commercial partnerships with global pharmaceutical leaders, and manufacturing innovations through the ProCellEx® platform.

Our curated news collection enables efficient monitoring of FDA submissions, earnings reports, and licensing agreements. Stay informed about the company's unique approach to cost-effective bioproduction and its expanding role in addressing unmet medical needs through plant-based protein expression systems.

Bookmark this page for direct access to verified press releases and objective analysis of Protalix's position within the competitive rare disease therapeutics market. Regular updates ensure you maintain current awareness of developments impacting both clinical outcomes and investment considerations.

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based expression system, has announced their participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.

The virtual conference is scheduled for March 25-26, 2025, featuring a two-day format with webcast presentations on the first day and one-on-one meetings between Protalix management and pre-qualified investors on the second day. The conference is organized by iAccess Alpha, which hosts virtual investor conferences for recommended companies.

Interested participants are advised to join the call 15 minutes early to complete necessary technical preparations. A recording of the presentation will remain accessible for at least six months through the Events Calendar in the Investors section of Protalix's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
conferences
-
Rhea-AI Summary

Protalix BioTherapeutics (PLX) reported strong financial results for fiscal year 2024, with record revenues from goods sales reaching $53.0 million, a 31% increase from 2023. The growth was primarily driven by an $11.8 million increase in sales to Chiesi.

Research and development expenses decreased 24% to $13.0 million, while selling, general and administrative expenses fell 19% to $12.2 million. The company reported net income of $2.9 million ($0.04 per share) compared to $8.3 million in 2023.

Key developments include successful completion of First-in-Human phase I trial for PRX-115 (gout treatment candidate), full repayment of outstanding debt, and EMA validation of pegunigalsidase alfa variation submission for less frequent dosing in Fabry disease. The company ended 2024 with $34.8 million in cash and equivalents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based protein expression system, has scheduled the release of its fiscal year 2024 financial results for March 17, 2025.

The company will host a conference call and webcast at 8:30 a.m. EDT on the same day, where management will discuss financial results and provide updates on corporate and regulatory developments. The call will feature a Call me™ functionality for easy access, and a replay will be available for two weeks on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, has announced its participation in the 2025 BIO CEO & Investor Conference.

The event will take place on February 10-11, 2025, at the New York Marriott Marquis. Company management will deliver a corporate presentation on Tuesday, February 11, 2025, at 10:15 AM EST in the Royale Room. The presentation will subsequently be made available in the Investors section of the company's website under the Event Calendar tab.

Management will also be available for one-on-one meetings with registered investors and conference attendees. Interested parties are encouraged to schedule meetings through the BIO CEO attendee portal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
conferences
-
Rhea-AI Summary

Protalix BioTherapeutics (PLX) released its 2025 stockholder letter highlighting key achievements in 2024 and future outlook. The company reports significant progress in its partnership with Chiesi Global Rare Diseases, including EMA's validation of a variation submission for pegunigalsidase alfa to enable less frequent dosing for Fabry disease patients. PLX completed a phase I trial for PRX-115 for uncontrolled gout, with plans to advance to phase II in H2 2025.

The company reports growth in sales across its three revenue streams: Elfabrio® to Chiesi, Elelyso® to Pfizer, and Uplyso® to Brazil. Notably, PLX has achieved debt-free status by fully repaying all outstanding convertible notes. Despite regional conflicts in Israel, operations remain uninterrupted, and the company maintains its focus on R&D in renal rare diseases using its ProCellEx platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
-
Rhea-AI Summary

Chiesi Global Rare Diseases and Protalix BioTherapeutics (PLX) announced the European Medicines Agency's validation of their Variation Submission for pegunigalsidase alfa. The submission aims to approve a less frequent dosing regimen of 2 mg/kg every four weeks for adult Fabry disease patients, compared to the current 1 mg/kg every two weeks.

The application is supported by a revised Population-PK model, exposure-response analyses, and clinical data from the Phase 3 BRIGHT study and its ongoing extension study. The studies investigated the 2 mg/kg every four weeks dosing in adult Fabry disease patients previously treated with agalsidase-alfa or -beta.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
Rhea-AI Summary

Protalix BioTherapeutics (PLX) reported Q3 2024 financial results with revenues from goods of $17.8 million, a 75% increase from Q3 2023. The company achieved net income of $3.2 million ($0.04 per share basic). Key highlights include completion of all eight cohorts in the PRX-115 phase I trial for uncontrolled gout treatment, showing promising preliminary results with sustained uric acid reduction. Cash position stands at $27.4 million as of September 30, 2024. The company fully repaid its 7.50% Senior Secured Convertible Notes and plans to initiate a phase II clinical trial for PRX-115 in the second half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.71%
Tags
-
Rhea-AI Summary

Protalix BioTherapeutics (PLX) has scheduled the release of its third quarter 2024 financial results and business update for November 14, 2024. The company will host a conference call and webcast at 8:30 a.m. EST to discuss financial results and provide updates on corporate and regulatory developments. The event will be accessible via toll-free numbers for domestic and international callers, with a Call me™ feature available for immediate connection. A two-week replay will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American:PLX) announced it will present data from its phase I clinical trial of PRX-115, a recombinant PEGylated uricase product candidate for uncontrolled gout treatment, at the ACR Convergence 2024. The presentation, titled 'Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115,' will be delivered as a late-breaking poster on November 18, 2024. The study focuses on participants with elevated urate levels, and the results will be presented by Dr. Orit Cohen Barak from Protalix.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
conferences clinical trial
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.

Company President and CEO Dror Bashan will deliver a presentation on Wednesday, September 11, at 12:30 p.m. EDT in the Holmes II Room on the Fourth floor. The management team will also engage in one-on-one meetings with registered investors throughout the conference.

Protalix is known for its proprietary ProCellEx® plant cell-based protein expression system, which is used in the development and production of recombinant therapeutic proteins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
conferences
Protalix Biother

NYSE:PLX

PLX Rankings

PLX Stock Data

203.67M
67.34M
13.7%
5.98%
6.86%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
HACKENSACK